Daily growth hormone is a medicine that can be prescribed for patients with growth hormone deficiency (pGHD). It is known to improve the symptoms associated with pGHD, including hyperglycemia and sleep apnea. However, there are certain risks involved with using this drug, such as an increased risk of cancer.
TransCon GH as an alternative to daily Omnitrope
In our review of TransCon GH, we found a few intriguing tidbits, including the fact that the company’s GH solution enables its users to administer more than 20 milligrams of GH with only a few minutes of prep time. This may be of particular interest to physicians and nurses who manage the care of patients with chronic renal insufficiency, a condition which can occur in patients undergoing transplantation.
The TransCon GH’s new dosing scheme has also allowed for easier administration of its GH solutions. For instance, the new formula can be administered by oral dosing in a similar fashion to a normal dose of saline, or can be administered by intravenous injection if preferred. Similarly, the GH solution can be applied at any time of the day or night. The company’s GH solutions are also accompanied by a complete menu of offerings, including a line of anti-hyperglycemia medications. These are particularly beneficial for patients suffering from Type 1 and Type 2 diabetes. As with the rest of the product line, the company’s GH solutions are all backed by a full service, on-site laboratory and a friendly customer service department. With the help of these resources, the GH solutions have proven themselves worthy of the company’s unrivaled commitment to providing quality healthcare. The GH solutions are available to doctors and nurses in the shortest of time frames, making the company a convenient and trusted partner for both patient and physician.
Long-acting growth hormones as a potential treatment for pGHD
Long-acting growth hormones (LAGH) are long-lasting molecules that act as a potential treatment for pediatric growth hormone deficiency (PGHD) in children. In addition to the obvious benefits of longer lasting GH therapy, these products are also able to potentially mitigate the challenges associated with treatment non-adherence.
Pediatric GHD is a rare condition that is associated with impaired musculoskeletal development and cardiovascular disease. Despite being associated with a large health care burden, many patients remain untreated. Therefore, it is important to identify the factors associated with non-adherence and develop strategies to address them.
One of the major barriers to treatment non-adherence is adherence to daily injections. Studies have shown that individuals with PGHD and children with idiopathic short stature have reduced adherence to GH over time. This is likely to limit treatment outcomes. There are several strategies that may improve adherence, including shared decision making, patient and family involvement, and comfort with the daily injections.
The development of LAGHs for PGHD is an important step in the ongoing research on the treatment of growth deficiencies. However, future studies will be needed to understand the impact of hypoglycemia in patients with PGHD. Also, it is important to note that these studies have not been conducted in other growth disorders.
Although the use of daily recombinant human GH was approved for adult GHD in 1996, daily treatment has been unavailable for children with GHD. Instead, daily somatropin injections have been used to treat this condition.
A variety of new long-acting GH therapies have recently been developed for adults and children with PGHD. These include a hybrid Fc-fused rhGH (Fc-ffrhGH), eftansomatropin alfa, and somapacitan. All three are being evaluated as potential treatments for pGHD.
In a recent clinical trial, somapacitan was shown to be non-inferior to daily GH for height velocity. Additionally, once weekly somatrogon has been found to yield non-inferior height velocities.
Several other LAGH products are in development, including rhGH fusion proteins and a prodrug. Some of these therapies are intended to reduce the number of injections required, which may be a more suitable approach for PGHD.
Sleep apnea and/or hyperglycemia
Many people have heard about sleep apnea, but what is it exactly and how does it affect your glucose levels? Sleep apnea is a disorder in which the breathing of an individual is repeatedly interrupted during the course of a night’s sleep. It is most common in people with diabetes, although it can also occur in non-diabetics. People with sleep apnea are at a higher risk for obesity and metabolic syndrome. If you suffer from obstructive sleep apnea, you may not be able to get enough oxygen to your brain, and the lack of oxygen can cause brain damage. The good news is that treatment can help.
Some studies have suggested that a special sleep mask can be used to increase air pressure in the throat. This can increase blood flow to the brain, which in turn can improve memory and mood. Aside from its obvious benefits, a sleep mask can help you snore better.
Sleep apnea and hyperglycemia do not necessarily go hand in hand, but they can be related. In one study, 56 percent of people with OSA had a history of diabetes. Interestingly, 55 percent of the participants had a sleep apnea severe enough to require medical attention. Even if the condition is not threatening, the increased pressure in the air passages can constrict the airway, which is bad for the respiratory system.
In short, there are many potential ways in which sleep apnea and hyperglycemia can interact. To avoid complications, it’s important to understand the nuances of the situation. One such strategy is to rely on multidisciplinary teams to identify and correct any underlying medical issues. Likewise, people with type 2 diabetes are at a greater risk of developing sleep apnea, as are those with pre-diabetes. These individuals also tend to have more sleep deprivation, which may also lead to more frequent bouts of sleep apnea. Similarly, patients with diabetes are more likely to exhibit REM-related OSA, which in turn can trigger hypoglycemia. Thus, it is not surprising that a person with sleep apnea is at a higher risk of heart disease.